| K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer CS Karapetis, S Khambata-Ford, DJ Jonker, CJ O'Callaghan, D Tu, ... New England Journal of Medicine 359 (17), 1757-1765, 2008 | 4494 | 2008 |
| Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration W Abida, A Patnaik, D Campbell, J Shapiro, AH Bryce, R McDermott, ... Journal of Clinical Oncology 38 (32), 3763-3772, 2020 | 575 | 2020 |
| Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer J Tie, JD Cohen, K Lahouel, SN Lo, Y Wang, S Kosmider, R Wong, ... New England Journal of Medicine 386 (24), 2261-2272, 2022 | 468 | 2022 |
| Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 … W Abida, D Campbell, A Patnaik, JD Shapiro, B Sautois, NJ Vogelzang, ... Clinical Cancer Research 26 (11), 2487-2496, 2020 | 348 | 2020 |
| Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel JD Shapiro, MJ Millward, D Rischin, M Michael, V Walcher, PA Francis, ... Gynecologic oncology 63 (1), 89-93, 1996 | 295 | 1996 |
| PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 CS Karapetis, D Jonker, M Daneshmand, JE Hanson, CJ O'Callaghan, ... Clinical Cancer Research 20 (3), 744-753, 2014 | 190 | 2014 |
| Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial DJ Jonker, L Nott, T Yoshino, S Gill, J Shapiro, A Ohtsu, J Zalcberg, ... The lancet Gastroenterology & hepatology 3 (4), 263-270, 2018 | 149 | 2018 |
| A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously … L Lim, P Gibbs, D Yip, JD Shapiro, R Dowling, D Smith, A Little, W Bailey, ... BMC cancer 5, 1-6, 2005 | 148 | 2005 |
| Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall and KRAS-Specific Results of the NCIC CTG and … HJ Au, CS Karapetis, CJ O'Callaghan, D Tu, MJ Moore, JR Zalcberg, ... Journal of Clinical Oncology 27 (11), 1822-1828, 2009 | 128 | 2009 |
| Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild … LL Siu, JD Shapiro, DJ Jonker, CS Karapetis, JR Zalcberg, J Simes, ... J Clin Oncol 31 (19), 2477-2484, 2013 | 126 | 2013 |
| Management of advanced gastric cancer TJ Price, JD Shapiro, E Segelov, CS Karapetis, N Pavlakis, E Van Cutsem, ... Expert review of gastroenterology & hepatology 6 (2), 199-209, 2012 | 104 | 2012 |
| The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic … T Prasanna, CS Karapetis, D Roder, J Tie, R Padbury, T Price, R Wong, ... Acta Oncologica 57 (11), 1438-1444, 2018 | 102 | 2018 |
| Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous … W Abida, AH Bryce, NJ Vogelzang, RJ Amato, JD Shapiro, R McDermott, ... Annals of Oncology 29, viii272, 2018 | 94 | 2018 |
| Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer DJ Jonker, CS Karapetis, C Harbison, CJ O'Callaghan, D Tu, RJ Simes, ... British journal of cancer 110 (3), 648-655, 2014 | 94 | 2014 |
| A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma M Peeters, AH Strickland, M Lichinitser, AVS Suresh, G Manikhas, ... British journal of cancer 108 (3), 503-511, 2013 | 90 | 2013 |
| Acute renal failure in critical illness conventional dialysis versus acute continuous hemodiafiltration R BELLOMO, D MANSFIELD, S RUMBLE, J SHAPIRO, G PARKIN, ... ASAIO journal 38 (3), M654-M657, 1992 | 86 | 1992 |
| Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies L Lim, P Gibbs, D Yip, JD Shapiro, R Dowling, D Smith, A Little, W Bailey, ... Internal medicine journal 35 (4), 222-227, 2005 | 85 | 2005 |
| Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC … W Abida, D Campbell, A Patnaik, B Sautois, J Shapiro, NJ Vogelzang, ... Annals of Oncology 30, v327-v328, 2019 | 83 | 2019 |
| A randomized controlled trial of a nurse-led supportive care package (SurvivorCare) for survivors of colorectal cancer M Jefford, K Gough, A Drosdowsky, L Russell, S Aranda, P Butow, ... The oncologist 21 (8), 1014-1023, 2016 | 78 | 2016 |
| Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal L Lim, M Chao, J Shapiro, JL Millar, D Kipp, A Rezo, A Fong, IT Jones, ... Diseases of the colon & rectum 50 (12), 2032-2039, 2007 | 75 | 2007 |
